Wells Fargo’s Briacell Therapeutics BCTX Stock Holding History

Wells Fargo’s Portfolio BCTX Stock Details BCTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3	Hold	1	–	–	﹤0.01%	7185
2026 Q1	$4	Hold	1	–	–	﹤0.01%	7037
2025 Q4	$7	Hold	1	–	–	﹤0.01%	6923
2025 Q3	$11	Sell	1 -2	-67%	-$21	﹤0.01%	6820
2025 Q2	$94	Hold	3	–	–	﹤0.01%	6485
2025 Q1	$116	Buy	3 +1	+50%	+$48	﹤0.01%	6360
2024 Q4	$164	Hold	2	–	–	﹤0.01%	6381
2024 Q3	$360	Buy	+2	New	+$225	﹤0.01%	6190

Other funds holding BCTX

CCC

Cable Car Capital San Francisco, California $4.66B AUM 77.16% 1-Year Est. Return

Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return

IAM

Iridian Asset Management Westport, Connecticut $291M AUM 49.45% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

LCM

LuminArx Capital Management New York $224M AUM

National Bank of Canada Montreal, Quebec, Canada $140B AUM 46.34% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

FDCDDQ

Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $32.7B AUM 35.71% 1-Year Est. Return

Wells Fargo's BCTX Position: Q2 2026 in Review

Wells Fargo held its Briacell Therapeutics (BCTX) position steady in Q2 2026 at 1 share worth $3. The position accounts for ﹤0.01% of the portfolio, ranked #7185.

Wells Fargo first reported a position in BCTX in Q3 2024 and has held it in 8 quarters since. The position peaked at $360 in Q3 2024. 19 funds tracked by Wall St. Rank hold BCTX as of Q2 2026.

Wells Fargo held 1 share of Briacell Therapeutics worth $3 as of Q2 2026.
Wells Fargo left its Briacell Therapeutics share count unchanged in Q2 2026.
Briacell Therapeutics made up ﹤0.01% of Wells Fargo's portfolio in Q2 2026, its #7185 holding.
Wells Fargo first reported a position in Briacell Therapeutics in Q3 2024 and has held it in 8 quarters since.
Wells Fargo's Briacell Therapeutics position peaked at $360 in Q3 2024.
19 funds tracked by Wall St. Rank held Briacell Therapeutics as of Q2 2026.

Based on Wells Fargo's 13F filing for Q2 2026, filed 14 Aug 2026.